查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612883

导管相关血流感染市场：按药物类别、给药途径、适应症、分销管道划分 - 全球预测 2025-2030 年

Catheter-related Bloodstream Infections Market by Drug Class (Cefazoline, Ceftazidime, Cloxacillin), Route of Administration (Injectable, Oral), Indication, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年导管相关血流感染市场价值为16.4亿美元，预计2024年将达到17.4亿美元，复合年增长率为5.88%，2030年将达24.6亿美元。

导管相关血流感染 (CRBSI) 是医疗机构中的一个重大问题，需要持续的市场研究来寻找预防和治疗解决方案。 CRBSI 的范围包括确定感染源、制定预防策略和加强治疗通讯协定，影响寻求最大限度降低感染率的医院和医疗保健提供者。由于导管相关手术的数量不断增加以及加护病房患者的脆弱性日益增加，该市场变得极为重要。主要应用包括使用先进的抗菌导管、涂层和锁定解决方案来降低感染率。最终用途主要包括医院、专科诊所和门诊病人中心。导管设计和涂层技术的进步提高了安全性，以及需要导管治疗的慢性疾病的盛行率不断增加，推动了市场成长。

主要市场统计
基准年[2023] 16.4亿美元
预计年份 [2024] 17.4亿美元
预测年份 [2030] 24.6亿美元
复合年增长率（%） 5.88%

关键的成长要素包括感染控制意识的提高和更严格的监管指南。随着政府卫生支出的增加和私人研发投资的增加，有开发具有成本效益且高效的预防措施和治疗方法的重大机会。然而，他们也面临挑战，例如先进医疗设备的高成本、潜在的副作用以及创新解决方案研发的复杂性。最新的潜在商机围绕着人工智慧和机器学习的集成，用于感染风险的预测分析，以及开发用于即时监测 CRBSI 的下一代生物感测器。

为了持续成长，公司应专注于与医疗机构的合作，进行试验计画来测试新技术，并收集真实的有效性资料。此外，探索研究经费和创新津贴的伙伴关係可以进一步加速市场采用。然而，报销问题和复杂的监管途径等限制可能会阻碍快速发展。特别是在全球永续性趋势下，生物相容性和环保导管材料的创新是推动产业进步和市场渗透的一个有前景的研究领域。 CRBSI 市场充满挑战，但对于那些能够驾驭其复杂性并投资前瞻性解决方案的公司来说充满了机会。

市场动态：快速发展的导管相关血流感染市场的关键市场洞察

供需的动态交互作用正在改变导管相关的血流感染市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 人们越来越关注静脉内细菌感染以及对有效治疗方案的需求
    • 提高对导管相关血流的认识宣传活动
  • 市场限制因素
    • 关于药品核准和产品召回案例的严格政府法规
  • 市场机会
    • 政府针对细菌性行为感染的有利措施和政策
    • 开发新药的药物传递和研发活动的进展
  • 市场挑战
    • 导管相关的血流感染过敏原和与药物相关的严重健康问题

波特五力：驾驭导管相关血流感染市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解导管相关血流感染市场的外部影响

外部宏观环境因素在塑造导管相关血流感染市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解导管相关血流感染市场的竞争状况

对导管相关血流感染市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵导管相关血流感染市场供应商的绩效评估

FPNV定位矩阵是评估导管相关血流感染市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，绘製导管相关血流感染市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对导管相关血流感染市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对静脉细菌感染疾病的日益关注以及对有效治疗方法的需求
      • 提高对导管相关血流的认识宣传活动
    • 抑制因素
      • 有关药品核准和产品召回的严格政府法规
    • 机会
      • 首选政府针对细菌感染疾病的措施和政策
      • 持续进行研究和开发活动，以推动药物输送和开发新药的进步
    • 任务
      • 导管相关的血流感染过敏原和与药物相关的严重健康问题
  • 市场区隔分析
    • 药物类别：广泛使用Cefazolin和氯唑西林药物治疗导管引起的细菌感染疾病
    • 适应症：人们对有效管理以及预防和治疗病毒和寄生虫感染疾病的兴趣日益浓厚
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的导管相关血流感染市场

  • Cefazolin
  • 头孢他齐健身房
  • 氯唑西林
  • Daptomycin
  • Echinocandins
  • Teicoplanin
  • 万古霉素

第七章导管相关血流感染市场：依给药途径

  • 可注射的
  • 口服

第八章导管相关血流感染市场（按适应症）

  • 细菌感染疾病
  • 霉菌感染疾病
  • 病毒和寄生虫感染疾病

第九章导管相关血流感染市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第10章美洲导管相关血流感染市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区导管相关血流感染市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲导管相关血流感染市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Citius Pharmaceuticals 宣布完成 Mino-Lok 用于缓解感染导管的 3 期研究的招募
    • BD 与 Bactiguard 合作，增强全球感染预防Foley导管的可及性
    • FDA核准DefenCath 是预防血液透析机病人导管相关血流感染的重要一步。
  • 战略分析和建议

公司名单

  • Advacare Pharma
  • AstraZeneca PLC
  • Bactiguard AB
  • Becton, Dickinson and Company
  • CorMedix Inc
  • Fresenius Medical Care AG
  • Glenmark Pharmaceuticals Ltd.
  • IntegraDose Compounding Services, LLC
  • Johnson & Johnson Services, Inc
  • JoinHub Pharma
  • Lupin Ltd.
  • Lyka Hetero Healthcare Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • TauroPhar GmbH
  • Xellia Pharmaceuticals Ltd.
Product Code: MRR-5D693B46C67B

The Catheter-related Bloodstream Infections Market was valued at USD 1.64 billion in 2023, expected to reach USD 1.74 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 2.46 billion by 2030.

Catheter-related bloodstream infections (CRBSIs) represent a significant concern in healthcare settings, necessitating ongoing market research into preventive and therapeutic solutions. The scope of CRBSI involves identifying sources, developing preventive strategies, and enhancing treatment protocols, impacting hospitals and healthcare providers aiming to minimize infection rates. This market is crucial due to the rising number of catheter-related procedures and the increased vulnerability of patients in intensive care units. Key applications involve the utilization of advanced antimicrobial catheters, coatings, and lock solutions aimed at reducing infection incidence. End-use primarily spans hospitals, specialty clinics, and outpatient centers. Market growth is driven by technological advancements in catheter designs and coatings that offer improved safety, along with the increasing prevalence of chronic diseases necessitating catheterization.

KEY MARKET STATISTICS
Base Year [2023] USD 1.64 billion
Estimated Year [2024] USD 1.74 billion
Forecast Year [2030] USD 2.46 billion
CAGR (%) 5.88%

Key growth influencers include heightened awareness and stringent regulatory guidelines focusing on infection control. There is a substantial opportunity in developing cost-effective and efficient preventive measures and treatments, backed by increasing governmental healthcare expenditures and private investments in research and innovation. However, the market also faces challenges such as high costs associated with advanced medical devices, potential side effects, and the complex nature of R&D for innovative solutions. The latest potential opportunities revolve around the integration of AI and machine learning for predictive analysis in infection risk as well as the development of next-generation biosensors for real-time monitoring of CRBSIs.

For continued growth, businesses should focus on collaborations with healthcare facilities to implement pilot programs testing new technologies and gathering real-world efficacy data. Additionally, exploring partnerships for research funding and innovation grants could further propel market adoption. Nevertheless, limitations such as reimbursement issues and the intricate nature of navigating regulatory pathways could impede rapid development. Innovating in biocompatible and eco-friendly materials for catheters, particularly amid global sustainability trends, presents a promising research area to leverage industry advancement and market penetration. The CRBSI market, though challenging, remains ripe with opportunities for those able to navigate its complexities and invest in forward-thinking solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Catheter-related Bloodstream Infections Market

The Catheter-related Bloodstream Infections Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing concerns about intravenous bacterial infections and the need for effective treatment options
    • Growing number of educational campaigns for awareness of catheter-related bloodstream
  • Market Restraints
    • Strict government regulations related to drug approvals and cases of product recalls
  • Market Opportunities
    • Favorable government initiatives and policies for bacterial infectious diseases
    • Advancements in the drug delivery and ongoing R&D activities for the novel drug development
  • Market Challenges
    • Allergens and significant health concerns associated with catheter-related bloodstream infections medications

Porter's Five Forces: A Strategic Tool for Navigating the Catheter-related Bloodstream Infections Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Catheter-related Bloodstream Infections Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Catheter-related Bloodstream Infections Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Catheter-related Bloodstream Infections Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Catheter-related Bloodstream Infections Market

A detailed market share analysis in the Catheter-related Bloodstream Infections Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Catheter-related Bloodstream Infections Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Catheter-related Bloodstream Infections Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Catheter-related Bloodstream Infections Market

A strategic analysis of the Catheter-related Bloodstream Infections Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Catheter-related Bloodstream Infections Market, highlighting leading vendors and their innovative profiles. These include Advacare Pharma, AstraZeneca PLC, Bactiguard AB, Becton, Dickinson and Company, CorMedix Inc, Fresenius Medical Care AG, Glenmark Pharmaceuticals Ltd., IntegraDose Compounding Services, LLC, Johnson & Johnson Services, Inc, JoinHub Pharma, Lupin Ltd., Lyka Hetero Healthcare Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, TauroPhar GmbH, and Xellia Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Catheter-related Bloodstream Infections Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Cefazoline, Ceftazidime, Cloxacillin, Daptomycin, Echinocandin, Teicoplanin, and Vancomycin.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Indication, market is studied across Bacterial Infections, Fungal Infection, and Viral & Parasitic Infections.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing concerns about intravenous bacterial infections and the need for effective treatment options
      • 5.1.1.2. Growing number of educational campaigns for awareness of catheter-related bloodstream
    • 5.1.2. Restraints
      • 5.1.2.1. Strict government regulations related to drug approvals and cases of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable government initiatives and policies for bacterial infectious diseases
      • 5.1.3.2. Advancements in the drug delivery and ongoing R&D activities for the novel drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Allergens and significant health concerns associated with catheter-related bloodstream infections medications
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Extensive utililzation of Cefazoline and Cloxacillin medication in the treatment of bacterial infections caused by catheter
    • 5.2.2. Indication: Growing focus on the effective management and the prevention and treatment of viral & parasitic infections
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Catheter-related Bloodstream Infections Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Cefazoline
  • 6.3. Ceftazidime
  • 6.4. Cloxacillin
  • 6.5. Daptomycin
  • 6.6. Echinocandin
  • 6.7. Teicoplanin
  • 6.8. Vancomycin

7. Catheter-related Bloodstream Infections Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Catheter-related Bloodstream Infections Market, by Indication

  • 8.1. Introduction
  • 8.2. Bacterial Infections
  • 8.3. Fungal Infection
  • 8.4. Viral & Parasitic Infections

9. Catheter-related Bloodstream Infections Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Catheter-related Bloodstream Infections Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Catheter-related Bloodstream Infections Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Catheter-related Bloodstream Infections Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Citius Pharmaceuticals Announces Completion of Phase 3 Trial Enrollment for Mino-Lok, Aiming to Salvage Infected Catheters
    • 13.3.2. BD Partners with Bactiguard to Enhance Global Access to Infection-Preventing Foley Catheters
    • 13.3.3. FDA Approval of DefenCath Marks a Significant Step in Catheter-Related Bloodstream Infection Prevention for Hemodialysis Patients
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Advacare Pharma
  • 2. AstraZeneca PLC
  • 3. Bactiguard AB
  • 4. Becton, Dickinson and Company
  • 5. CorMedix Inc
  • 6. Fresenius Medical Care AG
  • 7. Glenmark Pharmaceuticals Ltd.
  • 8. IntegraDose Compounding Services, LLC
  • 9. Johnson & Johnson Services, Inc
  • 10. JoinHub Pharma
  • 11. Lupin Ltd.
  • 12. Lyka Hetero Healthcare Ltd.
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Sanofi SA
  • 17. TauroPhar GmbH
  • 18. Xellia Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET RESEARCH PROCESS
  • FIGURE 2. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET DYNAMICS
  • TABLE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFAZOLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CLOXACILLIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ECHINOCANDIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY FUNGAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VIRAL & PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2023